Phase 2
๐ Investigational Drug / Biologic
NCT06511908
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
๐ National Institutes of Health Clinical Center โ Bethesda, Maryland
View Study & Screener โ